News Medical's "Thought Leaders" series is a selection of articles written by national and
international experts and trusted advisers in the life sciences industry. All the articles are
written by experts who have been invited as recognised leaders in their fields to provide
a "state of the art" contribution.
In our bioanalytical mass spectrometry lab we use proteomics techniques to try to understand more about Alzheimer's disease. The primary thrust of our research is that we're interested in understanding the changes that take place outside of the brain and how those correlate with what's taking place inside the brain
The main objective of our research is to improve and individualize cancer diagnostics and cancer treatment. We try to achieve this through the integrated use of MR technology and the development of data-driven tools to analyze tumors on both a functional and molecular level.
Head and neck cancers (HNC) are the sixth most common cancers worldwide, with approximately 600,000 new cases diagnosed every year.
Many Chamorro villagers on the island of Guam perished from a puzzling paralytic disease that combines aspects of ALS, Alzheimer's, and Parkinson's disease.
In around 2004, there was a Phillips paper that discussed a new imaging technique called MPI. At that time, I had an eager, promising graduate student named Matt Ferguson who wanted a project, so I asked him to take a look.
Most proteins are involved in interactions with one or a few functional ligands, but some proteins, like light chain 8 (LC8), have numerous binding partners. LC8 interacts with more than 100 functionally different proteins, from viral proteins to motor proteins to proteins involved in cell division.
I'm a professor in the Department of Integrative Structural and Computational Biology at The Scripps Research Institute. I have been performing NMR research on proteins for nearly 40 years.
I’m Björn Wängler, Professor for Molecular Imaging and Radiochemistry at the medical faculty Mannheim of Heidelberg University. I’m a radiopharmaceutical chemist by background and completed my PhD in 2004 at the University of Mainz.
Flow Cytometry, the measurement of various cellular characteristics as they flow through a measuring apparatus, has so many applications that it's hard to know where to begin.
Single fluorescent molecules provide a local nanometer-sized probe of complex systems. We can measure the motion of the single molecule, use them to achieve imaging on a scale down to 20 nanometers, or we can infer aspects of the behaviour of the object under study by the details of the light that is emitted.
The scope of the activity of neuropeptides is remarkably broad. For example, neuropeptides are involved in pain control, mood/depression/eating disorders, social and emotional behaviour, body weight, drug abuse, stress, reproduction, motor control, memory, and in maintaining neuronal health when they are stressed.
My laboratory’s long standing interest is the study of the signaling capabilities of stem cells, both under homeostatic conditions
Electrochemical methods are appealing because simple and inexpensive instrumentation can be used to make highly sensitive measurements. However, it has been quite difficult to realize clinically-relevant levels of sensitivity using electrochemistry in highly complex, real-world samples.
For about the last 25 years, the cardiology group here have been developing a platform technology for both the diagnosis and treatment of atherosclerosis. The group began at Northwestern University, Chicago, under the direction of Dr. David McPherson and he continues to lead the group.
Hi my name is Christina Thomas, we're here at the Institute of Clinical Chemistry in Munich. Our research focuses on interleukin 1 and the inflammasome and their role in innate immunity and inflammation.
Up to now, we've seen a lot of improvements made, but now we're almost at the point of focusing on the application of MPI and proving what the real benefits of this technology are, which is very exciting...
The CLIRSPEC network is a UK Engineering and Physical Sciences Research Council (EPSRC – EP/L012952/1) funded network in clinical infrared and Raman spectroscopy. Infrared and Raman spectroscopy can identify the hallmarks of disease and distinguish between diseased and non-diseased samples based upon inherent chemistry.
I’m Dr Panagiotopoulos and I am a resident at the University Hospital of Schleswig-Holstein. I work in the Radiological and Nuclear Medicine Department, at the Lübeck campus.
I am Mauro Magnani, Professor of Biochemistry at the University of Urbino, Italy. My background is essentially the transition of activity from the lab to application. I am also the founder of a spin-off company called EryDel, which uses technology to load materials or drugs inside cells.
I'm Jeff Bulte, professor of Radiology and Director of Cellular Imaging at the Institute for Cell Engineering at Johns Hopkins University School of Medicine, Baltimore, Maryland in the United States. I lead a group of about 20 to 25 people who focus their research on imaging cells.